A 50-year-old male emigrated from Laos to California in the 1980s. Thirty years later, he was diagnosed with nephrotic range proteinuria due to membranoproliferative glomerulonephritis. In addition to medications for gout, anemia, hypertension, and a pulmonary embolism, he was started on prednisone (60 mg daily) and mycophenolate mofetil (1000 mg twice daily). Three months later, he presented with melena, weakness, left upper quadrant abdominal pain, fever, and hypotension. His blood pressure was 80/57 mmHg. Laboratory workup revealed a hemoglobin of 4.2 mg/dL, a mean corpuscular volume of 76, and a white blood cell count of $11.8 \times 10^9$ cells/L without eosinophilia. His renal function was at baseline, with the rest of the blood chemistry, including liver enzymes, within normal limits. Computed tomography of the abdomen was unremarkable. Esophagoduodenoscopy and colonoscopy demonstrated mild esophagitis, patchy ileitis, and ulcers in the gastric atrium, splenic flexure, descending colon, sigmoid colon, and rectosigmoid area. Histopathology of duodenal biopsies is shown in Figs 1 and 2.

What is your diagnosis?
Diagnosis

*Strongyloides stercoralis* hyperinfection

The duodenal biopsy showed patchy mild chronic inflammation, villous edema, villous blunting, and parasites within crypts, consistent with *Strongyloides stercoralis* infection. Two stool specimens were negative for ova and parasites by trichrome stain; however, *Strongyloides* serology (IgG) was positive by enzyme-linked immunosorbent assay (ELISA, Quest Diagnostics, Valencia, California). Human immunodeficiency virus (HIV) antibody screening was negative, as was polymerase chain reaction for human T-cell lymphotropic virus (HTLV) I and II DNA. The patient received seven days of oral ivermectin (200 μg/kg daily).

Chronic strongyloidiasis can be asymptomatic or manifest with minimal gastrointestinal or cutaneous symptoms in people living in endemic areas. The decades-long infection begins with filariform larvae of *Strongyloides* penetrating intact skin. They are transported hematogenously to the lungs, penetrating alveolar spaces. Ascending to the trachea and pharynx, they are swallowed and transported to the small intestine, where larvae become adult female worms producing eggs, which yield rhabditiform larvae. Rhabditiform larvae may be passed in the stool or cause autoinfection of the host by transforming to infective filariform larvae, which can penetrate intestinal mucosa or the skin of the perianal area, once again [1,2]. Thus, the life cycle of the nematode is complete within the human host and may coexist without detection in endemic regions such as Laos, where reported prevalence ranges from 4%–41% [3–5].

Migrants seen at GeoSentinel clinics in all regions of the world have had strongyloidiasis at a rate of about 5% [6]. Detection of larvae remains the gold standard for confirming the diagnosis but has low sensitivity; obtaining three or more successive stool samples for ova and parasites is recommended, as a single stool examination fails to detect larvae in up to 70% of cases. While serologic testing is useful, antibodies can cross react with other nematode infections and do not distinguish between recent and previously treated infections [7]. Real-time polymerase chain reaction (RT-PCR) is a promising diagnostic method that detects *Strongyloides*
DNA in stool samples as a confirmatory method to follow serologic screening in nonendemic areas [8].

Hyperinfection is accelerated by immunosuppression, be it corticosteroids, HIV, HTLV-1, hematologic malignancy, or organ transplantation. Any subject coming from an endemic area must be screened for Strongyloides, at least with serology, before starting any immune suppressant and particularly corticosteroids [9–11]. Gastrointestinal mucosal ulceration may lead to massive hemorrhage and resultant mortality rates as high as 50%–70% [10,12]. Endoscopic biopsy reveals parasites in the gastric crypts or duodenal glands with eosinophilic infiltration of the lamina propria. Ivermectin is the first-line treatment, with a recommended dose of 200 μg/kg orally for one to two days for acute and chronic strongyloidiasis, but longer courses are needed in hyperinfection in the setting of immunosuppression [12–15].

Our patient recovered from strongyloidiasis, but his health was subsequently affected by reactivation of hepatitis B virus, multidermatomal varicella zoster, and disseminated nocardiosis with cutaneous, pancreatic, pulmonary, cerebral, and cerebellar involvement. Remarkably, he recovered from these infections as well and is now maintained on hemodialysis for end-stage renal disease.

Key teaching points

- Chronic strongyloidiasis can persist asymptomatically for many years, even for life, when a population of adult worms is maintained in the small intestine of people living in endemic areas.

- In immunosuppressed individuals, severe, disseminated strongyloidiasis can occur as infective larvae invade the tissues of the duodenum and jejunum and circulate throughout the body, causing widespread organ damage. Individuals from endemic areas must be screened for strongyloides with serology prior to commencing immune suppression.

- Ivermectin is highly efficacious and is the drug of choice for therapy. Parasitological cure is similar with thiabendazole, but its use is limited by toxicities and adverse effects.

References

1. Brooker SJ, Bundy DA. Soil-transmitted helminths (Geohelminths). In: Farrar J, Hotez P, Junghanss T, Kang G, Laloo D, White NJ. Manson’s Tropical Diseases. 23rd edition. Elsevier; 2014:766–795.
2. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004; 17:208–217. https://doi.org/10.1128/CMR.17.1.208-217.2004 PMID: 14726461
3. Vonghachack Y, Sayasone S, Bouakhaisith D, Taisayavong K, Akkavong K, Odermatt P. Epidemiology of Strongyloides stercoralis on Mekong islands in southern Laos. Acta Trop. 2015; 141(B): 289–94. https://doi.org/10.3347/kjp.2017.55.5.523 PMID: 29103267
4. Ribas A, Jollivet C, Morand S, et al. Intestinal parasitic infections and environmental water contamination in a rural village of Northern Lao PDR. Korean J Parasitol. 2017; 55(5):523–532. https://doi.org/10.3347/kjp.2017.55.5.523 PMID: 29103267
5. Conlan JV, Khamlome B, Vongxay K, et al. Soil-transmitted helminthiasis in Laos: a community-wide cross-sectional study of humans and dogs in a mass drug administration environment. Am J Trop Med Hyg. 2012; 86(4):624–34. https://doi.org/10.4269/ajtmh.2012.11-0413 PMID: 22492147
6. McCarthy AE, Weld LH, Barnett ED, et al. Spectrum of illness in international migrants seen at GeoSentinel clinics in 1997–2009, Part 2. Migrants resettled internationally and evaluated for specific health concerns. Clin Infect Dis. 2013; 56: 925–933. https://doi.org/10.1093/cid/cis1016 PMID: 23223602
7. Requena-Méndez A, Chiodini P, Bisoffi Z, et al. The laboratory diagnosis and follow up of strongyloidiasis: a systematic review. PLoS Negl Trop Dis. 2013; 7(1): e2002. https://doi.org/10.1371/journal.pntd.0002002 PMID: 23350004

8. Buonfrate D, Perandin F, Formenti F, Bisoffi Z. A retrospective study comparing agar plate culture, indirect immunofluorescence and real-time PCR for the diagnosis of Strongyloides stercoralis infection. Parasitology. 2017 May; 144(6):812–816. https://doi.org/10.1017/S0031182016002559 PMID: 28073382

9. Abanyie FA, Valice E, Delli Carpini KW, et al. Organ donor screening practices for Strongyloides stercoralis infection among US organ procurement organizations. Transpl Infect Dis. 2018; e12865. https://doi.org/10.1111/tid.12865 PMID: 29512242

10. Schwartz BS, Mawhorter SD; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. Am J Transplant. 2013 Mar; 13 Suppl 4:280–303.

11. Requena-Mendez A, Buonfrate D, Gomez-Junyent J, et al. Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries. Am J Trop Med Hyg. 2017 Sep; 97(3):645–652. https://doi.org/10.4269/ajtmh.16-0923 PMID: 28749768

12. Randi BA, Felicio MF, Lazari CS, et al. A woman with AIDS and a neglected disease presenting with coma, periumbilical purpuric rash, and alveolar hemorrhage. Clin Infect Dis. 2016; 63(9):1262–1263. https://doi.org/10.1093/cid/ciw435 PMID: 27742713

13. Donadello K, Cristallini S, Taccone FS, et al. Strongyloides disseminated infection successfully treated with parenteral ivermectin: case report with drug concentration measurements and review of the literature. Int J Antimicrob Agents. 2013; 42(6):580–583. https://doi.org/10.1016/j.ijantimicag.2013.07.015 PMID: 24269075

14. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis. 2009; 49(9):1411–23. https://doi.org/10.1086/630201 PMID: 19807271

15. Henríquez-Camacho C, Gotuzzo E, Echevarría J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016 Jan 18; (1): 1–50. https://doi.org/10.1002/14651858.CD012199